Cardiovascular effects of dl-1-(2-acetyl-4-butyramido-phenoxy)-2-hydroxy-3-isopropylaminopropane (M & B 17,803A), a new cardioselective beta adrenoreceptor blocking agent.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000813:Anilides / Q000494:pharmacology; D000818:Animals; D000889:Anti-Arrhythmia Agents; D002319:Cardiovascular System / Q000187:drug effects*; D003331:Coronary Vessels / Q000187:drug effects; D004285:Dogs; D004983:Ethanolamines / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D009206:Myocardium / Q000378:metabolism; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D010101:Oxygen Consumption / Q000187:drug effects; D010647:Phenyl Ethers / Q000494:pharmacology; D011437:Propylamines / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D000813:Anilides; D000889:Anti-Arrhythmia Agents; D004983:Ethanolamines; D010647:Phenyl Ethers; D011437:Propylamines; D009638:Norepinephrine